Volume 52, Issue 1 pp. 24-34
Original Study

Clinical and angiographic outcome in the laser angioplasty for restenotic stents (LARS) multicenter registry

Satyendra Giri MD

Corresponding Author

Satyendra Giri MD

Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts

L2, Cardiac Catheterization Laboratory, Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02215Search for more papers by this author
Shigenori Ito MD

Shigenori Ito MD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Alexandra J. Lansky MD

Alexandra J. Lansky MD

Lenox Hill Hospital, New York

Search for more papers by this author
Roxana Mehran MD

Roxana Mehran MD

Lenox Hill Hospital, New York

Search for more papers by this author
James Margolis MD

James Margolis MD

Miami Heart Institute, Miami, Florida

Search for more papers by this author
Paul Gilmore MD

Paul Gilmore MD

University Medical Center, Jacksonville, Florida

Search for more papers by this author
Kirk N. Garratt MD

Kirk N. Garratt MD

Mayo Clinic, Rochester, Minneapolis

Search for more papers by this author
Frank Cummins MD

Frank Cummins MD

Milwaukee Heart and Vascular Institute, Milwaukee, Wisconsin

Search for more papers by this author
Jeffrey Moses MD

Jeffrey Moses MD

Lenox Hill Hospital, New York

Search for more papers by this author
Peter Rentrop MD

Peter Rentrop MD

St. Vincent's Hospital, New York

Search for more papers by this author
Stephen Oesterle MD

Stephen Oesterle MD

Stanford University, Stanford, California

Search for more papers by this author
John Power MD

John Power MD

St. Francis Hospital, Pittsburgh, Pennsylvania

Search for more papers by this author
Kenneth M. Kent MD, PhD

Kenneth M. Kent MD, PhD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Lowell F. Satler MD

Lowell F. Satler MD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Augusto D. Pichard MD

Augusto D. Pichard MD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Hongsheng Wu PhD

Hongsheng Wu PhD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Ann Greenberg

Ann Greenberg

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Theresa A. Bucher

Theresa A. Bucher

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
William Kerker

William Kerker

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Andrea S. Abizaid MD

Andrea S. Abizaid MD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Jorge Saucedo MD

Jorge Saucedo MD

Department of Internal Medicine, Cardiology Divisions, Washington Hospital Center, Washington, D.C.

Search for more papers by this author
Martin B. Leon MD

Martin B. Leon MD

Lenox Hill Hospital, New York

Search for more papers by this author
Jeffrey J. Popma MD

Jeffrey J. Popma MD

Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts

Search for more papers by this author

Abstract

In-stent restenosis (ISR), when treated with balloon angioplasty (PTCA) alone, has an angiographic recurrence rate of 30%–85%. Ablating the hypertrophic neointimal tissue prior to PTCA is an attractive alternative, yet the late outcomes of such treatment have not been fully determined. This multicenter case control study assessed the angiographic and clinical outcomes of 157 consecutive procedures in 146 patients with ISR at nine institutions treated with either PTCA alone (n = 64) or excimer laser assisted coronary angioplasty (ELCA, n = 93)) for ISR. Demographics were similar except more unstable angina at presentation in ELCA-treated patients (74.5% vs. 63.5%; P = 0.141). Lesions selected for ELCA were longer (16.8 ± 11.2 mm vs. 11.2 ± 8.6 mm; P < 0.001), more complex (ACC/AHA type C: 35.1% vs. 13.6%; P < 0.001), and with compromised antegrade flow (TIMI flow < 3: 18.9% vs. 4.5%; P = 0.008) compared to PTCA-treated patients. ELCA-treated patients had similar rate of procedural success [93 (98.9% vs. 62 (98.4%); P = 1.0] and major clinical complications [1 (1.1%) vs. 1 (1.6%); P = 1.0]. At 30 days, repeat target site coronary intervention was lower in ELCA-treated patients (1.1% vs. 6.4% in PTCA-treated patients; P = 0.158), but not significantly so. At 1 year, ELCA-treated patients had similar rate of major cardiac events (39.1% vs. 45.2%; P = 0.456) and target lesion revascularization (30.0% vs. 32.3%; P = 0.646). These data suggest that ELCA in patients with complex in-stent restenosis is as safe and effective as balloon angioplasty alone. Despite higher lesion complexity in ELCA-treated patients, no increase in event rates was observed. Future studies should evaluate the relative benefit of ELCA over PTCA alone for the prevention of symptom recurrence specifically in patients with complex in-stent restenosis. Cathet Cardiovasc Intervent 2001;52:24–34. © 2001 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.